Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains one of the currently
available curative therapies for acute leukemia (AL). Leukemia relapse is one of the mainly
causes of transplant failure. We reported previously that patients with relapse or refractory
AL were at very high risk of relapse post allo-HSCT, with cumulative relapse rate of 50-80%.
Decitabine has been demonstrated efficacy in the treatment of patients with recurrent or
refractory leukemia and myelodysplastic syndrome. It was reported that the combination of
decitabine, with busulfan and cyclophosphamide as a preparative regimen for allo-HSCT using
HLA-matching donors was safe and effective. In this prospective, single-arm clinical trial,
we aimed to examine the efficacy of combining decitabine with modified busulfan and
cyclophosphamide (mBU/CY) as a preparative regimen for allo-HSCT in recurrent and refractory
AL patients.